| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRD5a2 |
| Uniprot No | P31213 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-65aa |
| 氨基酸序列 | AKPSGYGKHTESLKPAATRLPARAAWFLQELPSFAVPA |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SRD5A2重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**：*"Expression, purification, and characterization of human steroid 5α-reductase type 2 in Escherichia coli"*
**作者**：Li X, Chen C, Singh SM, Labrie F
**摘要**：该研究报道了在大肠杆菌中高效表达人源SRD5A2重组蛋白的方法，并通过亲和层析纯化获得活性酶。实验验证了重组蛋白的催化活性，证明其可将睾酮转化为二氢睾酮(DHT)，并探讨了pH和抑制剂对其活性的影响。
2. **文献名称**：*"Structural insights into human steroid 5α-reductase 2 pathogenesis and inhibition by small molecules"*
**作者**：Lolli ML, Cacciatore M, Di Leva FS, et al.
**摘要**：通过昆虫细胞表达系统获得SRD5A2重组蛋白，结合X射线晶体学解析其三维结构。研究揭示了酶活性位点的关键氨基酸残基，并基于结构筛选了新型小分子抑制剂，为治疗雄激素相关疾病提供依据。
3. **文献名称**：*"Functional analysis of missense mutations in SRD5A2 causing 46.XY disorders of sex development"*
**作者**：Uemura M, Tamura K, Chung BC, et al.
**摘要**：利用哺乳动物细胞(HEK293)重组表达携带不同突变的SRD5A2蛋白，评估其酶活性和稳定性。结果表明，部分突变导致蛋白错误折叠或催化功能丧失，为基因型-表型关联提供了分子机制解释。
---
如需更具体的文献或实验细节，建议在PubMed或Web of Science中以“SRD5A2 recombinant protein”为关键词进一步检索。
The SRD5A2 (steroid 5α-reductase type 2) recombinant protein is derived from the human SRD5A2 gene, which encodes a critical enzyme in steroid metabolism. This membrane-bound enzyme catalyzes the irreversible conversion of testosterone to dihydrotestosterone (DHT), a potent androgen essential for male sexual development and function. SRD5A2 is predominantly expressed in androgen-sensitive tissues such as the prostate, genital skin, and seminal vesicles. Its role in regulating DHT levels links it to conditions like benign prostatic hyperplasia (BPH), androgenetic alopecia, and prostate cancer.
Recombinant SRD5A2 protein is produced using heterologous expression systems (e.g., mammalian cells, bacteria, or yeast) to enable large-scale, standardized studies. Purified SRD5A2 retains enzymatic activity, allowing researchers to investigate its kinetics, substrate specificity, and interactions with inhibitors like finasteride or dutasteride—drugs used clinically to block DHT production.
Research on SRD5A2 recombinant protein has advanced understanding of genetic disorders such as 5α-reductase deficiency, a rare autosomal recessive condition causing undervirilization in males. It also aids in drug discovery, structural studies, and biochemical assays to evaluate therapeutic compounds targeting androgen-related pathologies. The ability to produce functional recombinant SRD5A2 has been pivotal in elucidating its physiological and pathological roles, offering insights into personalized treatments for hormone-dependent diseases.
×
